{{Rsnum
|rsid=6481464
|Gene=FAM13C
|Chromosome=10
|position=61120484
|Orientation=plus
|GMAF=0.3411
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 66.4 | 29.2 | 4.4
| HCB | 29.4 | 48.5 | 22.1
| JPT | 34.5 | 53.1 | 12.4
| YRI | 41.5 | 49.0 | 9.5
| ASW | 42.1 | 42.1 | 15.8
| CHB | 29.4 | 48.5 | 22.1
| CHD | 32.1 | 44.0 | 23.9
| GIH | 49.5 | 44.6 | 5.9
| LWK | 40.9 | 45.5 | 13.6
| MEX | 36.2 | 37.9 | 25.9
| MKK | 35.3 | 50.0 | 14.7
| TSI | 54.9 | 37.3 | 7.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6481464
|Name_s=
|Gene_s=FAM13C
|Feature=
|Evidence=PubMed ID:18439552
|Annotation=In a GWAS of subjects from the PARC study (Pharmacogenomics and Risk of Cardiovascular Disease), this was one of the ten SNPs most strongly associated with plasma C-reactive protein levels.
|Drugs=
|Drug Classes=
|Diseases=Cardiovascular Diseases
|Curation Level=Curated
|PharmGKB Accession ID=PA162399730
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6481464
|overall_frequency_n=37
|overall_frequency_d=128
|overall_frequency=0.289062
|n_genomes=31
|n_genomes_annotated=0
|n_haplomes=32
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}